CLINICAL TRIALS PROFILE FOR VESICARE
✉ Email this page to a colleague
All Clinical Trials for VESICARE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00333112 ↗ | A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. | Completed | Astellas Pharma Inc | Phase 4 | 2006-05-01 | A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men. |
NCT00368706 ↗ | A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients | Completed | Astellas Pharma Inc | Phase 3 | 2006-09-01 | To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid |
NCT00431041 ↗ | Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) | Completed | Astellas Pharma Canada, Inc. | Phase 4 | 2006-12-01 | The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB). |
NCT00431041 ↗ | Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) | Completed | Astellas Pharma Inc | Phase 4 | 2006-12-01 | The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB). |
NCT00454740 ↗ | Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder | Completed | Astellas Pharma Inc | Phase 3 | 2004-06-01 | To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes |
NCT00454896 ↗ | A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) | Completed | Astellas Pharma Inc | Phase 3 | 2004-05-01 | The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VESICARE
Condition Name
Clinical Trial Locations for VESICARE
Trials by Country
Clinical Trial Progress for VESICARE
Clinical Trial Phase
Clinical Trial Sponsors for VESICARE
Sponsor Name